Abstract
Inhibition of the growth of LoVo human colon adenocarcinoma and MiaPaCa pancreatic cancer cell lines by two new organometallic ruthenium(II) complexes of general formula [Ru(eta(5)-C(5)H(5))(PP) L][CF(3)SO(3)], where PP is 1,2-bis(diphenylphosphino)ethane and L is 1,3,5-triazine (Tzn) 1 or PP is 2x triphenylphosphine and L is pyridazine (Pyd) 2 has been investigated. Crystal structures of compounds 1 and 2 were determined by X-ray diffraction studies. Atomic force microscopy (AFM) images suggest different mechanisms of interaction with the plasmid pBR322 DNA; while the mode of binding of compound 1 could be intercalation between base pairs of DNA, compound 2 might be involved in a covalent bond formation with N from the purine base.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / metabolism
-
Antineoplastic Agents / pharmacology*
-
Cell Line, Tumor
-
Cell Proliferation / drug effects*
-
Cell Survival / drug effects
-
Colonic Neoplasms / metabolism
-
Crystallography, X-Ray
-
DNA / metabolism
-
Humans
-
Ligands
-
Microscopy, Atomic Force
-
Organometallic Compounds / chemical synthesis
-
Organometallic Compounds / chemistry
-
Organometallic Compounds / pharmacology*
-
Pancreatic Neoplasms / metabolism
-
Ruthenium / pharmacology*
Substances
-
(eta(5)-cyclopentadienyl)(1,2-bis(diphenylphosphine)ethane)(1,3,5-triazine)ruthenium(II)
-
(eta(5)-cyclopentadienyl)(pyridazine)bis(triphenyphosphine)ruthenium(II)
-
Antineoplastic Agents
-
Ligands
-
Organometallic Compounds
-
Ruthenium
-
DNA